Nuvation Bio Inc (NYSE:NUVB) Share Price

Company Profile

Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USA
T: +1 332 208-6102
https://www.nuvationbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
273

Recommended

As investors toil in complexity the obvious solution may be the right one.

Mark LaMonica, CFA | 24 July 2025

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.

Matthew Dolgin, CFA | 23 July 2025

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

John Abernethy | 23 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,934.30	45.10	-0.50%
CAC 40	7,834.58	16.30	0.21%
DAX 40	24,217.50	78.43	-0.32%
Dow JONES (US)	44,901.92	208.01	0.47%
FTSE 100	9,120.31	18.06	-0.20%
HKSE	25,388.35	278.83	-1.09%
NASDAQ	21,108.32	50.36	0.24%
Nikkei 225	41,456.23	370.11	-0.88%
NZX 50 Index	12,853.46	48.33	0.38%
S&P 500	6,388.64	25.29	0.40%
S&P/ASX 200	8,666.90	42.50	-0.49%
SSE Composite Index	3,593.66	12.07	-0.33%